Nephrogenic systemic fibrosis and gadolinium-based contrast agents

References

• Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet356, 1000–1001 (2000).
   PubMed Web of Science ®Google Scholar
• Levine JM, Taylor RA, Elman LB et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve30, 569–577 (2004).
   PubMed Web of Science ®Google Scholar
• Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin. Arthritis Rheum.35, 238–249 (2006).
   PubMed Web of Science ®Google Scholar
• Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am. J. Kidney Dis.46, 754–759 (2005).
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Artlett CM, Sandorfi N et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum.50, 2660–2666 (2004).
   PubMedGoogle Scholar
• Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch. Dermatol.139, 903–906 (2003).
   PubMedGoogle Scholar
• Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch. Pathol. Lab. Med.130, 209–212 (2006).
   PubMed Web of Science ®Google Scholar
• Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J. Am. Acad. Dermatol.48, 42–47 (2003).
   PubMed Web of Science ®Google Scholar
• Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am. J. Dermatopathol.23, 383–393 (2001).
   PubMed Web of Science ®Google Scholar
• Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am. J. Med.114, 563–572 (2003).
   PubMed Web of Science ®Google Scholar
• Dundova I, Treska V, Simanek V, Michal M. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc.37, 4187–4190 (2005).
   PubMed Web of Science ®Google Scholar
• Schmook T, Budde K, Ulrich C, Neumayer HH, Fritsche L, Stockfleth E. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol. Dial. Transplant.20, 220–222 (2005).
   PubMed Web of Science ®Google Scholar
• Maloo M, Abt P, Kashyap R et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am. J. Transplant.6, 2212–2217 (2006).
   PubMed Web of Science ®Google Scholar
• Chiu H, Wells G, Carag H, Canova E, Firpi RJ. Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transpl.10, 465–466 (2004).
   PubMedGoogle Scholar
• Baron PW, Cantos K, Hillebrand DJ et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am. J. Dermatopathol.25, 204–209 (2003).
   PubMed Web of Science ®Google Scholar
• Leboit P. What nephrogenic fibrosing dermopathy might be. Arch. Dermatol.139, 928–930 (2003).
   PubMedGoogle Scholar
• Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr. Opin. Rheumatol.48, 55–60 (2003).
   Google Scholar
• Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J. Am. Acad. Dermatol.48, 55–60 (2003).
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Ahmed I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann. Intern. Med.145, 234–235 (2006).
   PubMed Web of Science ®Google Scholar
• Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch. Dermatol.140, 1401 (2004).
   PubMedGoogle Scholar
• Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am. J. Clin. Dermatol.7, 237–247 (2006).
   PubMed Web of Science ®Google Scholar
• Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial. Transplant.21, 1104–1108 (2006).
   PubMed Web of Science ®Google Scholar
• Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J. Am. Soc. Nephrol.17, 2359–2362 (2006).
   PubMed Web of Science ®Google Scholar
• High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J. Am. Acad. Dermatol.56, 21–26 (2007).
   PubMed Web of Science ®Google Scholar
• Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J. Am. Acad. Dermatol.56, 27–30 (2007).
   PubMed Web of Science ®Google Scholar
• ‘Dear Doctor’ global letter. From Larry Bell, MD, Vice President and Global Head of Regulatory and Pharmacovigilance. GE Healthcare. Dated Dec 22, 2006.
   Google Scholar
• Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr. Nephrol.22(9), 1395 (2007).
   PubMed Web of Science ®Google Scholar
• Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am. J. Roentgenol.188, 586–592 (2007).
   PubMed Web of Science ®Google Scholar
• Sadowski EA, Bennett LK, Chan MR et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology243, 148–157 (2007).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents – St Louis, Missouri, 2002–2006. MMWR Morb. Mortal. Wkly. Rep.56, 137–141 (2007).
   PubMedGoogle Scholar
• Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest. Radiol.42, 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Pryor JG, Poggioli G, Galaria N et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J. Am. Acad. Dermatol.57(1), 105–111 (2007).
   PubMed Web of Science ®Google Scholar
• Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin. Exp. Dermatol.32(4), 353–358 (2007).
   PubMed Web of Science ®Google Scholar
• High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J. Am. Acad. Dermatol.56, 710–712 (2007).
   PubMed Web of Science ®Google Scholar
• Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin. J. Am. Soc. Nephrol.2, 264–267 (2007).
   PubMed Web of Science ®Google Scholar
• Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol. Rev.23, 231–247 (2001).
   PubMed Web of Science ®Google Scholar
• Neudecker BA, Stern R, Mark LA, Steinberg S. Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J. Cutan. Pathol.32, 612–615 (2005).
   PubMed Web of Science ®Google Scholar
• Edward M, Fitzgerald L, Thind C, Leman J, Burden AD. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br. J. Dermatol.156, 473–479 (2007).
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Ahmed I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann. Intern. Med.145, 234–235 (2006).
   PubMed Web of Science ®Google Scholar
• Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am. J. Pathol.163, 993–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case–control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol. Dial. Transplant. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Muroff LR. MRI contrast: current agents and issues. Appl. Radiol.30, 5–7 (2001).
   Google Scholar
• Krause U, Kroencke T, Spielhaupter E et al. Contrast-enhanced magnetic resonance angiography of the lower extremities: standard-dose vs. high-dose gadodiamide injection. J. Magn. Reson. Imaging21, 449–454 (2005).
   PubMed Web of Science ®Google Scholar
• Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology242, 647–649 (2007).
   PubMed Web of Science ®Google Scholar
• Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat. Clin. Pract. Nephrol.3, 111–115 (2007).
   PubMedGoogle Scholar
• Bloem JL, Wondergem J. Gd-DTPA as a contrast agent in CT. Radiology171, 578–579 (1989).
   PubMed Web of Science ®Google Scholar
• Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam. Clin. Pharmacol.20, 563–576 (2006).
   PubMed Web of Science ®Google Scholar
• Heppelman B, McDougall JJ. Inhibitory effect of amiloride and gadolinium on fine afferent nerves in the rat knee: evidence of mechanogated ion channels in joints. Exp. Brain Res.67, 114–118 (2005).
   Google Scholar
• Nordenbo AM, Somnier FE. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA. Lancet340, 1168 (1992).
   PubMedGoogle Scholar
• Maramattom BV, Manno EM, Wijdicks EF, Lindell EP. Gadolinium encephalopathy in a patient with renal failure. Neurology64, 1276–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest. Radiol.28(Suppl. 1) S28–S43 (1993).
   PubMed Web of Science ®Google Scholar
• Bousquet JC, Saini S, Stark DD et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology166, 693–698 (1988).
   PubMed Web of Science ®Google Scholar
• Tombach B, Bremer C, Reimer P et al. Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure. Invest. Radiol.35, 35–40 (2000).
   PubMed Web of Science ®Google Scholar
• Townsend RR, Cohen DL, Katholi R et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am. J. Kidney Dis.36, 1207–1212 (2000).
   PubMed Web of Science ®Google Scholar
• Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad. Radiol.5, 491–502 (1998).
   PubMed Web of Science ®Google Scholar
• Thomsen HS, Morcos SK. Nephrogenic systemic fibrosis and nonionic linear chelates. AJR Am. J. Roentgenol.188, W580–W581 (2007).
   Google Scholar
• Penfield J, Reilly RF Jr. What the nephrologist should know about gadolinium. Nat. Clin. Pract. Nephrol. (2007) (In press).
   PubMedGoogle Scholar
• Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn. Reson. Imaging8, 467–481 (1990).
   PubMed Web of Science ®Google Scholar
• Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest. Radiol.31, 739–742 (1996).
   PubMed Web of Science ®Google Scholar
• Vorobiov M, Basok A, Tovbin D, Shnaider A, Katchko L, Rogachev B. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol. Dial. Transplant.18, 884–887 (2003).
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Horn TD, Pellowski D et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N. Engl. J. Med.357, 720–722 (2007).
   Google Scholar
• Roditi G. Glasgow Royal Infirmary. Presented at: European Congress of Radiology. Vienna, Austria, 9–13 March 2007.
   Google Scholar
• Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br. J. Dermatol.150, 596–597 (2004).
   PubMed Web of Science ®Google Scholar
• Glaich AS, Martinelli PT, Markus RF, Hsu S. Generalized elastolysis following nephrogenic fibrosing dermopathy. J. Am. Acad. Dermatol.53, 174–176 (2005).
   PubMed Web of Science ®Google Scholar
• Edsall LC, English JC 3rd, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J. Cutan. Pathol.31, 247–253 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis KG, Lester BW, Pan TD, Robinson-Bostom L. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J. Cutan. Pathol.33, 695–700 (2006).
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Zeegers M, Segaert S et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol. Dial. Transplant.19, 469–473 (2004).
   PubMed Web of Science ®Google Scholar
• Falanga V, Medsger TA. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J. Am. Acad. Dermatol.17, 648–656 (1987).
   PubMed Web of Science ®Google Scholar
• DiCarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J. Am. Acad. Dermatol.54, 914–916 (2006).
   PubMed Web of Science ®Google Scholar
• Tan AW, Tan SH, Lian TY, et al. A case of nephrogenic fibrosing dermopathy. Ann. Acad. Med. Singapore33, 527–529 (2004).
   PubMed Web of Science ®Google Scholar
• Wahba IM, White K, Meyer M, Simpson EL. The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy – report of two cases and review of the literature. Nephrol. Dial. Transplant.22, 631–636 (2007).
   PubMed Web of Science ®Google Scholar
• Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like changes in four renal dialysis patients. Br. J. Dermatol.148, 563–568 (2003).
   PubMed Web of Science ®Google Scholar
• Kafi R, Fisher GJ, Quan T et al. UVA-1 phototherapy improves nephrogenic fibrosing dermopathy. Arch. Derm.140, 1322–1324 (2004).
   PubMedGoogle Scholar
• Läuchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology208, 278–280 (2004).
   PubMed Web of Science ®Google Scholar
• Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br. J. Dermatol.152, 531–536 (2005).
   PubMed Web of Science ®Google Scholar
• Baron PW, Cantos K, Hillebrand DJ et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am. J. Dermatopathol.25, 204–209 (2003).
   PubMed Web of Science ®Google Scholar
• Okada S, Katagiri K, Kumazaki T, Yokohama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol.42, 339–341 (2001).
   PubMed Web of Science ®Google Scholar
• Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure – role of gadolinium based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin. J. Am. Soc. Nephrol.2, 258–263 (2007).
   PubMed Web of Science ®Google Scholar
• Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin. Radiol.61, 905–906 (2006).
   PubMed Web of Science ®Google Scholar
• Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol.48, 593–596 (2007).
   PubMed Web of Science ®Google Scholar
• Henness S, Keating GM. Adis drug profile: gadofosveset. Drugs66, 851–857 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest. Radiol.41, 332–338 (2006).
   PubMed Web of Science ®Google Scholar
• Bridot JL, Faure AC, Laurent S et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J. Am. Chem. Soc.129, 5076–5084 (2007).
   PubMed Web of Science ®Google Scholar
• Li Z, Li W, Li X, Pei F, Wang X, Lei H. Mn(II)-monosubstituted polyoxometalates as candidates for contrast agents in magnetic resonance imaging. J. Inorg. Biochem. (2007).
   Google Scholar
• Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn. Reson. Imaging9, 275–283 (1991).
   PubMed Web of Science ®Google Scholar
• Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med.53, 999–1005 (2005).
   PubMed Web of Science ®Google Scholar